FDA Review Is Getting Less Predictable — Build the Regulatory-Intelligence SaaS That Helps

RegPath AI: See the gap before the FDA does.

FDA's own 2025 CDER report shows it met its PDUFA goal dates 96% of the time — but an independent RBC Capital Markets analysis found the quarterly approval rate fell to 73% in Q3 2025, down from 87%. RegPath AI is the 82-page business blueprint for building the AI-powered regulatory-intelligence and submission-readiness SaaS that helps biotech regulatory teams catch the gap between those two numbers — before it becomes a Complete Response Letter.

82 Pages Instant PDF Download 7-Day Guarantee 38% OFF Today

The FDA Predictability Gap, In Numbers

19
Complete Response Letters issued across 2025 (SinoDrugWatch analysis of published FDA CRLs)
8 vs 6
novel-drug rejections, H1 2026 vs. H1 2025 (BioSpace)
73%
Q3 2025 approval rate, down from 87% avg. (RBC Capital Markets, via STAT News)
96%
FDA's own full-year PDUFA goal-date rate for 2025 (CDER)

"RegPath AI never predicts or guarantees an FDA outcome. It surfaces cited, confidence-scored findings for a qualified regulatory affairs professional to review — every finding, every time."

Grounded in sourced FDA/CDER, RAPS, BioSpace & STAT News data
45 chapters + AI Prompt Library + worksheets
Decision-support positioning explained in plain English
7-day money-back guarantee
The Problem

Guidance changes. Documents drift out of sync. Nobody catches it until the CRL.

The gap isn't a shortage of regulatory expertise — it's the missing connective layer between a fast-moving guidance landscape and a submission draft built by a dozen contributors over many months.

Regulatory teams track FDA guidance manually — spreadsheets, email digests, and episodic consultants that don't cross-reference the company's actual submission.

Submissions are built by many contributors over months — doses, study numbers, and safety figures drift out of sync between modules without anyone noticing.

The traditional readiness review happens weeks before filing — too late to fix anything cheaply, let alone systematically.

Generic AI chat tools have no regulatory grounding, no citation discipline, and no audit trail — not something a risk-averse regulatory buyer can trust.

There's a gap between "AI could help regulatory teams" and "AI you can actually trust with a real FDA submission." RegPath AI is built for the gap.
The Solution

Meet RegPath AI

Continuous FDA guidance monitoring, connected directly to an AI-assisted, human-reviewed audit of the company's own IND/NDA/BLA drafts — never a prediction of what the FDA will decide.

  • Continuously tracks FDA guidance, safety communications & PDUFA milestones
  • AI-assisted submission-readiness audit with mandatory human review on every finding
  • A cited, confidence-scored Submission Readiness Score — not an LLM-generated verdict
  • A Guidance Impact Analyzer that resolves a guidance change to the exact documents it touches
  • A permanent human-review gate — the AI never submits or edits a document on its own
  • A per-seat annual SaaS model built for how regulatory affairs teams actually budget

Positioned as regulatory decision support, never as:

Not an FDA-approval predictor · Not an autonomous regulatory decision-maker · Not a replacement for regulatory affairs professionals · Not legal, financial, or regulatory advice.

82
pages, 45 chapters
45
parts + bonus & appendices
What's Included

The entire business, on paper

45 chapters across 45 parts, mirroring the ebook's actual table of contents — from the FDA predictability data to a 12-slide investor pitch.

The Opportunity & Customer

Ch. 1–3 — The regulatory-delay problem with sourced FDA/analyst data, ten detailed buyer personas, and a full Jobs-to-Be-Done framework.

The Product & AI Engine

Ch. 4–7 — All seven core modules including the flagship AI Submission-Readiness Audit, the AI architecture and hallucination-prevention design, and the regulatory intelligence pipeline.

Technical, Trust & Governance

Ch. 6, 8–9, 15–17 — Full MVP architecture, product UX for 16 screens, security/compliance controls (SOC 2, 21 CFR Part 11, GxP), AI governance, and legal positioning.

Business & Financial Model

Ch. 11–12, 27–29 — Per-seat pricing strategy, illustrative unit economics, KPIs, a 3-year financial projection, and a funding roadmap from bootstrap to Series A.

Build, Launch & Grow

Ch. 18–24, 30–37 — Go-to-market strategy, sales scripts, onboarding, a 12-slide pitch deck, landing-page & sales copy, a 90-day content plan, and the 10-step implementation playbook.

Lean Launch & Launch Toolkit

Ch. 38–45 — What not to build, the one-person startup version, the Concierge MVP bridge to SaaS, fictional sample reports/dashboards, brand development, the business moat, plus the AI Prompt Library, worksheets, and appendices.

Who This Is For

Built for a founder ready to build the real thing

RegPath AI's blueprint is written for a founder building a regulated B2B SaaS, and it stays grounded in the real regulatory affairs teams that product would serve.

Primary Reader

Biotech & Regulated-SaaS Founders

Someone seriously considering building a regulatory-intelligence or compliance SaaS and wanting a complete, realistic operating plan.

Regulatory Affairs & Quality Leaders

VPs, Directors, and Managers who want a fully worked example of buyer personas, product architecture, and a go-to-market plan for this exact category.

Technical Builders

Engineers and AI/ML builders who want the exact architecture pattern — RAG-grounded retrieval, a rules engine, and permanent human review as a design constraint.

Investors & Advisors

Anyone evaluating a regulatory-intelligence SaaS pitch who wants a rigorous, honest reference for what a well-built, well-governed one should cover.

Before / After

From "AI could help with regulatory affairs" to a real operating plan

Before RegPath AI

  • "AI could catch submission gaps" with no architecture, no pricing model, and no compliance map.
  • No plan for what happens when the AI is uncertain — or wrong.
  • No researched view of SOC 2, 21 CFR Part 11, or GxP exposure for this exact business model.
  • Unsourced FDA statistics repeated from outdated commentary.
  • No pilot design, no first-customers plan, no investor pitch — just an idea.

After RegPath AI

  • A complete, priced, modeled business plan with a named product, positioning, and architecture.
  • A permanent human-in-the-loop design and an AI governance framework (Chapters 5 & 16).
  • A security/compliance control set and legal positioning chapter (Chapters 15 & 17) — for counsel to finalize, not a substitute for it.
  • Every headline statistic sourced and labeled verified fact vs. assumption throughout.
  • A Concierge MVP bridge, a 90-day launch plan, and a 12-slide investor pitch, ready to execute against.
Pricing

Everything above, for one low one-time price

The Complete 82-Page Blueprint (45 chapters)$59
AI Prompt Library (70 prompts across 7 use-case categories)$25
Worksheets & Checklists (readiness, onboarding, launch)$15
4 Appendices — Glossary, Alternatives Cheat Sheet, FAQ & Templates$10
Total Value$79
38% OFF — Today Only

RegPath AI: The Complete Business Blueprint

$12.99$79

One-time payment · Instant PDF download · 82 pages

Get Instant Access — $12.99
Backed by a 7-day money-back guarantee

This is a one-time ebook purchase, not a subscription. Chapter 11 inside covers the recommended product's own per-seat annual SaaS pricing strategy for RegPath AI the platform — a separate number from this ebook's price.

Bonus Resources

Extras included at no extra cost

Bonus 1

AI Prompt Library

Bonus 2

Worksheets & Checklists

Bonus 3

Final Deliverables Summary

Bonus 4

Tool/Platform Alternatives Cheat Sheet

Bonus 5

Glossary & Communication Templates

Reviews

Just launched — reviews coming soon

RegPath AI is a brand-new release. We're not fabricating reviews — here's honest placeholder space until real readers weigh in.

Awaiting first reader review.

Reserved for a verified reader

Awaiting first reader review.

Reserved for a verified reader

Awaiting first reader review.

Reserved for a verified reader
FAQ

Questions, answered plainly

No. RegPath AI is the name of the product designed inside this blueprint. You're buying the 82-page ebook that teaches you how to build, price, launch, and scale a product like it — not a subscription to a live platform.
No — and it must never be marketed that way. The product designed in this book identifies candidate documentation gaps and risks for a qualified regulatory affairs professional to review and confirm (Chapters 4–5, 16–17). This blueprint is a business and product strategy document, not regulatory software or regulatory advice.
No. Nothing in this book is a guarantee of any business outcome. It's a complete, realistic operating plan and research base — statistics and financial projections are clearly labeled as verified facts or as modeled assumptions throughout.
Instant PDF download, 82 pages, delivered immediately after checkout.
It maps the relevant frameworks and issues in plain English (Chapter 15) — but it is not legal advice, and the book repeatedly recommends engaging qualified regulatory and legal counsel before launch and before handling real submission data.
You're covered by a 7-day money-back guarantee. Email sales@viralbydesign.co within 7 days of purchase for a full refund.

7-Day Money-Back Guarantee

If the file you receive is genuinely defective or doesn't match this description, request a refund within 7 days of purchase — email sales@viralbydesign.co. Because this is launch-priced digital delivery, please review the full details on our refund policy page before buying.

Stop guessing at the idea. Start building the business.

Get the complete RegPath AI blueprint — the research, the AI architecture, the compliance map, the pricing model, and the launch plan — for one low one-time price.

Get Instant Access — $12.99

Was $79 · 84% OFF today · Instant PDF download · 7-day money-back guarantee

$49 Get Instant Access